119 results about "D Glutamine" patented technology

The present disclosure provides formulations and methods for delivering water-soluble and lipid-soluble nutrients for preventing or correcting nutrient deficiencies to subjects requiring small-volume nutritional support, such as preterm infants. The formulations may comprise an emulsion of docosahexaenoic acid (DHA) stabilized by a protein emulsifier, such as α-lactalbumin, and may further comprise other valuable nutrients, such as arachidonic acid (ARA), arginine, glutamine, arginyl-glutamine dipeptide and/or alanyl-glutamine dipeptide. The formulation is useful, for example, for correcting nutritional deficiencies by increasing a subject's intake of nutrients such as ω-3 or ω-6 long-chain polyunsaturated acids, proteins, peptides, vitamins, minerals, other fatty acids, and/or essential amino acids. The nutritional formulation is suitable for enteral delivery and small-volume delivery via nasogastric tube, intragastric feeding, transpyloric administration and/or any other means of administration that result in the introduction of the nutritional formulation into the digestive tract of a subject.

A composition includes a plurality of amino acids. The plurality of amino acids includes at least one essential amino acid and at least one non-essential amino acid. The plurality of amino acids also includes at least one branch-chain amino acid. The composition also includes a source of carbohydrates. The compositions also includes purified water. The plurality of amino acids comprises about 1 wt % of the composition. A composition includes a plurality of amino acids, sodium citrate, sodium chloride, potassium phosphate, flavoring, a source of carbohydrates, and purified water. In some embodiments of the composition, the plurality of amino acids includes alanine, arginine, aspartate, cystine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonin, tryptophan, tyrosine, and valine.

A Family 6 cellulase variant enzyme comprising one or more than one amino acid substitution selected from a basic, polar or non-polar amino acid at position 103, a valine or isoleucine at position 136, a tyrosine at position 186, a glutamic acid or glutamine at position 365 and a glutamine at position 410 is provided (said position determined form alignment of the parental Family 6 with SEQ ID NO: 1). Genetic constructs and genetically modified microbes comprising DNA sequences encoding the Family 6 cellulase variant are also provided. Family 6 cellulases of the invention display reduced inhibition by glucose relative to the parent Family 6 cellulases. Such cellulases find use in a variety of applications in industry, e.g., in the hydrolysis of pretreated lignocellulosic feedstock, that require cellulose activity in the presence glucose concentrations that would otherwise inhibit the activity of the parental enzyme.

The invention discloses L-d-glutamic oxidase with substrate specificity and alpha-oxoglutarate produced by catalysis of the same, and belongs to the field of enzyme-method catalytic production of fine chemicals. The invention has the advantages that the L-d-glutamic oxidase which only has the substrate specificity to L-glutamic acid, L-sodium glutamate and glutamine is utilized, 20g/L L-sodium glutamate solution is added in fermented liquid which is fermented for 60 hours and contains the L-d-glutamic oxidase, carrying out conversion for 12 hours under the ventilating condition and the conditions that the temperature is 30 DEG C, the pH is 8.5 and the 5% (v/v) isopropyl alcohol, and measured by a high-performance liquid chromatography, the content of alpha-oxoglutarate reaches 14.5g/L.

Production of alanyl glutamine dipeptide compound is carried out by adding L-glutamine into mixed liquid of methylbenzene and water, cooling, adding into sodium hydrate, dissolving L-glutamine, dripping into solution with alpha - halopropacyl halide, methylbenzene and sodium hydrate, regulating pH, reacting, separating organic layer, adding sodium chloride into solution with organic layer separation, regulating pH, adding into concentrated chlorhydric acid, regulating pH, laying aside, filtering, separating out crystal, drying crystal, reacting with ammonia water, controlling temperature and pressure, cooling, de-pressuring, concentrating, adding water, dripping into methyl alcohol, laying aside, filtering, separating out L-alanyl-L-glutamate crude products, purifying and obtaining refined products. It achieves simple process and low cost.

The invention discloses a D-amino acid oxidase mutant and application thereof. The mutant is obtained by carrying out single mutagenesis or multiple mutagenesis on a 52nd site, a 54th site, a 58th site, a 213rd site and a 335th site of amino acid with an amino acid sequence shown in SEQ ID NO.1, wherein glycine at the 52nd site is mutated into leucine, asparagine at the 54th site is mutated into valine, phenylalanine at the 58th site is mutated into glutamine, methionine at the 213rd site is mutated into serine, and serine at the 335th site is mutated into glycine. According to the D-amino acid oxidase mutant and the application thereof, a D-amino acid oxidase gene with an amino acid sequence as shown in SEQ ID NO.2 is mutated by utilizing a site-saturation mutagenesis technology, so thatthe enzyme activity and the product conversion rate are far higher than those of a wild type, and therefore the product yield in a 4-(hydroxymethylphosphoryl)-2-carbonyl-butanoic acid production process is increased.

The invention discloses a method for preparing N(2)-L-alanyl-L-glutamine, belonging to a method for preparing dipeptide containing four amino acids at most. The method comprises the following steps: (1) inorganic base is added into the solution of toluene and water which contains L-glutamine; then the mixture of D-alpha-chloropropionyl chloride and toluene is added and the pH value of reaction solution is controlled between 9.5 and 10.5 by the inorganic base; the reaction temperature is maintained between 0-5 DEG C; the reaction solution is quiescent so that a toluene layer is separated; sodium chloride is added into the remaining solution at room temperature and N(2)-D-alpha-chloropropionyl-L-glutamine is obtained after filtration and drying; ammonia is added into the N (2)-D-alpha-chloropropionyl-L-glutamine, and concentrated solution after concentration under reduced pressure is transferred to a crystallizer; methanol is added and a crude product is obtained after filtration and drying; a refined product of the N (2)-L-alanyl-L-glutamine is obtained by refining.

The present invention relates to synthesis of dipeptide containing amino acid, and provides a kind of synthesis process of N(2)-L-alanyl-L-glutamine dipeptide with low material cost, simplicity, high yield, no need of separating and purifying intermediate product, easy product separation and purification and environment friendship. The synthesis process includes the reaction of amino acid with protected N-terminal with phosphorus triphenyl oxide and triphosgene in organic solvent to form active ester; the reaction of the active ester with glutamine in water solution of inorganic alkali; acidifying with inorganic acid and eliminating N-terminal protecting radical.

The invention provides a N(2)-L-alanyl-glutamine for injection and its preparing method, it has mixed N(2)-L-alanyl-glutamine and mannite to make N(2)-L-alanyl-glutamine whose mess percentage density is 50-100%. The invention has increased the stability of medicine greatly, convenient for transportation and storage, suitable for sicker in catabolism and hypermetabolism condition who needs glutamine.

The present invention is an immunostimulatory composition that bolsters or enhances the immune system in injured, diseased, traumatized or otherwise critically ill patients whose own immune system has been compromised thereby. The ready to feed, liquid formulation comprises glutamine which is stabilized and highly bioavailable in the form of a peptide bound glutamine. Other components comprise the free amino acids such as arginine, a nucleobase such as RNA and omega-3 and omega-6-polyunsaturated fatty acids.

Disclosed is a process for synthesis of L-glutamine which consists of, reacting ortho-phthalic anhydride and excess L-glutamine at 120-180 deg. C, obtaining phthaloyl-L-glutamine and L-pyroglutamic acid, separating to obtain L-pyroglutamic acid and phthaloyl-L-glutamine, subjecting the latter and acetic anhydride to azeotropy 3-30 minutes to form phthaloyl-L-glutamic acid anhydride, acting with stronger ammonia water directly at room temperature, obtaining phthaloyl-L-glutamine, charging hydrazine hydrate solution, dispensing 48 hours to remove the protective groups.

The invention discloses a method of producing L-alanyl-L-glutamine from recombinant escherichia coli, wherein the method of producing L-alanyl-L-glutamine from recombinant escherichia coli is follows: in an aqueous solution with a determined pH value, acting on free L-glutamine and L-alanine methyl ester hydrochloride to generate L-alanyl-L-glutamine, recombining a gene segment of the protein with the amino-acid ester acyltransferase of the L-alanyl-L-glutamine into a carrier and transferring into host bacteria, thereby obtaining the host bacteria with the recombinant DNA and capable of strengthening the activity of an L-alanyl-L-glutamine biological synthesis system. The method comprises the following steps: (1) culturing a larger number of recombinant escherichia coli cells for expressing the amino-acid ester acyltransferase; (2) excessively expressing the amino-acid ester acyltransferase in the step (1); and (3) taking the amino-acid ester acyltransferase in the step (2) as a crude enzyme source, adding the crude enzyme source into a buffer solution containing L-glutamine and L-alanine methyl ester hydrochloride substrate amino acid to react, thereby realizing efficient production of the L-alanyl-L-glutamine.

This invention relates to the use of a composition in low doses containing single L-amino acids, including their precursors and biologically still active metabolites, to influence the life processes of plants, such as their growth, whereby the total amount of single L-amino acids when applying the composition is at least 0.5 g/ha and at most 250 g/ha, and wherein the L-amino acids are selected from the group of glutamine, asparagine, aspartic acid, histidine, lysine, and combinations thereof with each other and/or with arginine and/or with glutamic acid.

A composition used as gastric mucosa protecting agent for treating acute or chronic gastritis, gastric ulcer, duodenal ulcer, etc is prepared from the water-soluble precursors including sodium azulenesulfonate and L-glutamine or glycyl-L-glutamine or L-alanyl-L-glutamine through proportioning and conventional steps.

The invention discloses an amino acid additive capable of improving the growth capacity and intestinal health of a weaned pig. The effective constituents of the amino acid additive include threonine, leucine, arginine, isoleucine and glutamine. By adding 0.5-1.0% of amino acid additive to the basic ration of the piglet, the intestinal structure of the piglet can be improved, synthesis of intestinal mucous protein is promoted, the immunity of the intestinal tract is improved, in this way, the intestinal health of the piglet is improved, the diarrhea rate is the piglet is lowered, and the growth capacity of the piglet is improved.

The present invention relates to enzyme process of synthesizing gamma-D-glutamyl-L-tryptophane. Gamma-glutamyltranspeptidase is first added into the substrate solution comprising L-tryptophane in 8-50 mmol/L and gamma-D-glutamie in 5-35 mmol/L to produce the peptide-converting reaction preparing gamma-D-glutamyl-L-tryptophane in 8 hr, and the prepared gamma-D-glutamyl-L-tryptophane is then separated and purified. The present invention has simple process, low cost, less side reactions, high gamma-D-glutamyl-L-tryptophane converting rate, high yield and high product purity, and may be used in industrial production.

Disclosed is a T7 RNA polymerase mutant having improved thermal stability and/or specific activity in comparison with wild-type T7-like bacteriophage RNA polymerase, wherein at least one amino acid residue corresponding to at least one of the amino acid residues selected from the group at least consisting of glutamine at position 768, lysine at position 179 and valine at position 685 of the amino acid sequence that composes wild-type T7 RNA polymerase shown in SEQ ID NO: 6, is substituted with another amino acid.

A modified glucose dehydrogenase is disclosed which comprises a water-soluble glucose dehydrogenase having a pyrroloquinoline quinone as a coenzyme. At least one amino acid residue present on the surface of the water-soluble glucose dehydrogenase is replaced with arginine. The side chain of the amino acid residue is exposed at the surface of the molecule and is not expected to substantially interact with other residues. The amino acid residue is present in a region that is probably not an enzyme active site or a substrate binding site. Preferably the amino acid residue is selected from the group consisting of glutamine, asparagine, and threonine. This modified enzyme can be prepared by recombinant processes and recovered efficiently.

The present invention relates to a protein hydrolysate comprising free amino acids and peptides whereby the weight ratio of free amino acids to peptides is about 1:1 and wherein at least about 50 molar % of the peptides has a molecular weight of 400 Da or less. This composition may be rich in one or more branched-chain amino acid-(BCAA-) and or glutamine-containing di- or tripeptides. Also, the invention relates to the use of a water soluble protein-containing aqueous fraction obtained from a wet-milling process or the protein hydrolysate in: the manufacture of a medicament for the treatment or prevention of a condition associated with inappropriate blood sugar metabolism; aiding recovery and/or endurance during or after exercise; stimulating the generation of lean body mass; infant nutrition; or the preparation of a food or feed composition or a food or feed supplement.

The invention provides a method for producing N-acetyl-L-glutamine, which comprises: dissolving L-glutamine in water, adding proper amount of catalyst, slowly adding acetic anhydride and a sodium hydroxide solution, adjusting the pH value to be between 7 and 12, and controlling the temperature to be between 5 and 80 DEG C, reacting for 1 to 3 hours, dropwise adding 6N hydrochloric acid to adjust the pH value to be between 0.5 and 3.0 after complete acylation, performing stirring, freezing and crystallization after concentration and de-watering until the temperature is between 0 and 10 DEG C, and performing centrifugation and drying to obtain coarse products; and dissolving the coarse products in deionized water of which the mass is 3 to 7 times of the coarse products, adding active carbon for decolorization, and obtaining finished products after filtration, concentration, crystallization, centrifugation and drying. Amino acid produced by the method has various pharmacological activities and clinic functions, has wide potential market, not only can greatly improve the production level of the amino acid in China but also has significance in improving the health level of people, and has high social benefit and economic benefit.

The invention relates to a synthetic method of N-fluorenylmethoxycarbonyl-N- triphenylmethyl-D-glutamine to solve the current problems of the shortage of D-Gln raw materials and high cost of synthesizing products from the D-Gln. The synthesis includes the following steps: a. D-glutamate and a carbobenzoxy chloride are reacted to get the N-carbobenzoxy-D-glutamate; in an organic solvent N and N-dimethylformamide with the existence of a triethylamine and bromomethyl-benzene, the N-carbobenzoxy-D-glutamate selectively protects an Alpha-carboxyl to get an N-benzyloxycarbonyl-D-benzyl L-glutamate; b. the triethylamine, ethyl chloroformate and ammonia are added to N- benzyloxycarbonyl-D- benzyl L-glutamate organic solvent with a molar ratio of 1:1:2 to 6; after reacted for 6 to 24 hours under a temperature of -20 to 20 DEG C, an N- benzyloxycarbonyl-D-glutaminebenzylester is gotten; c. the product of b, acetate liquor is reacted with a triphenylmethanol under a catalysis of concentrated sulfuric acid, and N- benzyloxycarbonyl-N-triphenylmethyl-D-glutaminebenzylester can be gotten after reacted for 8 to 24 hours under a temperature of 40 to 60 DEG C; d. benzyloxycarbonyl and benzyl are detracted from the product of c to get the N-triphenylmethyl-D-glutamine; e. the product of d is protected by an Fmoc group to get the N-fluorenylmethoxycarbonyl-N-triphenylmethyl-D- glutamine.

The invention discloses a composite amino acid vitamin injection and the application thereof. Every 1000ml of the composite amino acid vitamin injection comprises 5-40g of L-leucine, 2-30g of L-isoleucine, 2-30g of L-valine, 5-90g of L-alanyl-L-glutamine, 1-5g of L-threonin 1-10g of L-lysine, 1-12g of L-methionine, 1-10g of L-phenylalanine, 0.5-8g of L-tryptophan, 2-30g of L-arginine, 1-10g of L-histidine, 1-100mg of vitamin B6, 0-50mg of vitamin B1 and 0-100mu g of vitamin B12. Aiming at variation of stress, immunity, metabolism and the like of a human body in a perioperative anesthesia period, the composite amino acid vitamin injection achieves the purposes of inhibiting catabolism, promoting anabolism, generating heat and keeping warm, improving body substance energy metabolism and immunity functions and accelerating heal through creative formulae on the basis of enhanced recovery after surgery.